A comparison of anesthetic complications between diabetic and nondiabetic dogs undergoing phacoemulsification cataract surgery: a retrospective study

Objective To compare the incidence of anesthetic complications in diabetic and nondiabetic dogs undergoing general anesthesia and phacoemulsification cataract surgery. Procedure The medical and anesthetic records of all dogs undergoing phacoemulsification cataract surgery at Davies Veterinary Specialists between 2005 and 2008 were reviewed. Anesthetic records were evaluated by an ECVAA Diplomate. Dogs for which records were incomplete were excluded. The anesthetic technique, including all drugs administered in the perioperative period, was recorded. The anesthetic complications investigated included hypotension (MAP (mmHg): ≥55 none/mild; ≤54 moderate/severe), bradycardia (<60 bpm associated with hypotension) and hypothermia (esophageal temperature <36.7 °C). Where hypotension was present, the method of and response to treatment was recorded. The incidence of severe hyperglycemia (blood glucose >13.75 mmol/L (250 mg/dL)) in the diabetic group was also assessed. Results 66 diabetic and 64 nondiabetic dogs were included in the study. Diabetic dogs were more likely to develop moderate and severe intraoperative hypotension than nondiabetic dogs. Forty‐four percent of diabetic dogs had at least one episode of severe hyperglycemia whilst anesthetized. Conclusions Diabetic dogs undergoing phacoemulsification are more likely to suffer the anesthetic complications of moderate and severe hypotension than nondiabetic dogs. The increased incidence and severity of hypotension in diabetic dogs may be explained by hypovolemia secondary to hyperglycemia and resultant osmotic diuresis.     

Comparison of regular insulin infusion doses in critically ill diabetic cats: 29 cases (1999–2007)

Objective – To compare biochemical parameters, neurologic changes, length of hospital stay, and clinical improvement in 3 groups of cats with diabetic ketosis/diabetic ketoacidosis (DK/DKA) prescribed varied doses of regular insulin as a continuous rate of infusion (CRI). Design – Retrospective study. Setting – University teaching hospital. Animals – Twenty‐nine client‐owned cats with DK/DKA prescribed a regular insulin CRI. Interventions – Cats were grouped as follows: 7 cats each in Group 1 and 2, (prescribed 1.1 and 2.2 U/kg/d, respectively), and 15 cats in Group 3 (prescribed increasing doses as needed). Measurements and Main Results – None of the groups received the total prescribed dose of insulin. The mean actual dose administered/kg/d ranged from 0.30 (0.21) to 0.87 (0.32) U/kg/d in Groups 1, 2, and 3. There was no difference in mean minimum blood glucose (BG) per 4 hours or change in BG from baseline per 4 hours between Groups 1 and 2 (P=0.63, 0.50). There was no difference between groups regarding the time required to reach a BG ≤13.9 mmol/L (250 mg/dL), serum phosphorus or potassium concentrations relative to baseline values (P=0.53, 0.90), length of time until urine or serum ketones were no longer detected (P=0.73), the animal commenced eating (P=0.24), or length of hospital stay (P=0.63). Four of the cats had declining mentation during hospitalization; there were no relationships between osmolality at presentation, either prescribed or administered insulin dose, and mentation changes. Three of the 4 cats with declining mentation survived. Twenty‐seven of the 29 cats (93%) survived to discharge. Conclusions – In this study, prescribing the published canine dose (2.2 U/kg/d) of regular insulin to cats with DK/DKA does not appear to increase the frequency of adverse neurologic or biochemical sequelae compared with cats that are prescribed the published cat dose (1.1 U/kg/d). The use of a sliding scale for determination of infusion rates significantly reduces the amount of insulin cats receive in this setting. Determination of whether adverse sequelae would occur more frequently if cats with DK/DKA received the full insulin prescribed doses of 1.1, 2.2, or >2.2 U/kg/d is warranted. Further controlled studies are necessary to determine if higher doses of insulin are associated with beneficial effects on morbidity or mortality.     

UCPs基因多态性与脂肪代谢的相关性研究

解偶联蛋白(uncoupling protein,UCPs)是线粒体内膜上具有调节质子跨膜转运作用的载体蛋白,在调节动物能量代谢、脂肪沉积及脂肪酸氧化等方面起着重要作用。到目前为止,至少有5种(UCP1、UCP2、UCP3、UCP4和UCP5)这个家族的蛋白质已经在人类、哺乳动物、禽类、鱼甚至在植物的不同组织线粒体的内膜上被发现。UCPs在能量代谢动态平衡中、机体生热作用、肥胖、糖尿病及自由基代谢中起到重要的作用,解偶联蛋白基因已经被列为参与能量代谢和体温调节的候选基因。大量的研究报道了人类UCPs基因突变对脂肪代谢、糖尿病及其并发症、肥胖症的影响。作者从UCP1、UCP2及UCP3基因的定位、结构、分布、基因的多态突变与脂肪代谢、糖尿病及肥胖症之间的相关性研究进行了综述。     

食(药)用菌抗糖尿病研究进展

食(药)用菌具有降血糖、抗癌等多种药理作用。随着糖尿病发病率的攀升,对于其降血糖活性的研究日益受到重视。综述了国内外对虫草、姬松茸、桦褐孔菌、灵芝、灰树花、黑木耳、猴头菌等一系列食(药)用菌的降血糖功效及机理作用研究,以期为食(药)用菌在抗糖尿病方面的研究及应用提供参考。     

Effect of wheat bran supplementation on blood sugar,glycosylated protein and serum lipids in NIDDM subjects

Wheat bran supplementation (11 gm per day) was carried out for a period of two months in 30 maturity onset diebetics. The efficacy of bran supplementation was monitored by measuring the fasting and 2 h post prandial blood sugar levels, glycosylated serum protein levels, glycosylated albumin levels and serum lipid and lipoprotein cholesterol levels. The results indicated a transient reduction in fasting and 2 h post prandial blood sugar levels after one month's bran therapy. No appreciable changes in the serum glycosylated protein levels, glycosylated albumin levels, serum lipids and lipoprotein cholesterol levels were observed during the period of supplementation.Abbreviations TC total cholesterol - HDL-C high density lipoprotein cholesterol - LDL-C low density lipoprotein cholesterol - VLDL-C Very low density lipoprotein cholesterol - TG triglycerides - PL phospholipids - FFA free fatty acids - G-Alb glycosylated albumin - GSP glycosylated serum proteins - NIDDM Non Insulin Dependent Diabetes Melitus     

The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats

The glucagon-like peptide-1 mimetic exenatide has a glucose-dependent insulinotropic effect, and it is effective in controlling blood glucose (BG) with minimal side effects in people with type 2 diabetes. Exenatide also delays gastric emptying, increases satiety, and improves β-cell function. We studied the effect of exenatide on insulin secretion during euglycemia and hyperglycemia in cats. Nine young, healthy, neutered, purpose-bred cats were used in a randomized, cross-over design. BG concentrations during an oral glucose tolerance test were determined in these cats previously. Two isoglycemic glucose clamps (mimicking the BG concentration during the oral glucose tolerance test) were performed in each cat on separate days, one without prior treatment (IGC) and the second with exenatide (1 μg/kg) injected subcutaneously 2 h before (ExIGC). BG, insulin, and exenatide concentrations were measured, and glucose infusion rates were recorded and compared in paired tests between the two experiments. After exenatide injection, insulin serum concentrations increased significantly (2.4-fold; range 1.0- to 9.2-fold; P = 0.004) within 15 min. This was followed by a mild decrease in BG concentration and a return of insulin concentration to baseline despite a continuous increase in serum exenatide concentrations. Insulin area under the curve (AUC) during ExIGC was significantly higher than insulin AUC during IGC (AUC ratio, 2.0 ± 0.4; P = 0.03). Total glucose infused was not significantly different between IGC and ExIGC. Exenatide was detectable in plasma at 15 min after injection. The mean exenatide concentration peaked at 45 min and then returned to baseline by 75 min. Exenatide was still detectable in the serum of three of five cats 8 h after injection. No adverse reactions to exenatide were observed. In conclusion, exenatide affects insulin secretion in cats in a glucose-dependent manner, similar to its effect in other species. Although this effect was not accompanied by a greater ability to dispose of an intravenous glucose infusion, other potentially beneficial effects of exenatide on pancreatic β cells, mainly increasing their proliferation and survival, should be investigated in cats.     

家蚕预蛹粉对糖尿病模型小鼠的降血糖效果试验

利用变态发育至预蛹期的家蚕制备预蛹粉及脱脂预蛹粉,并添加至饲料中饲喂四氧嘧啶诱导糖尿病模型小鼠,观测小鼠血糖值及基本生理状况和主要脏器指数的改变。试验组糖尿病模型小鼠饲喂添加5%家蚕预蛹粉的饲料后,其"三多一少"症状有显著改善,肝脏指数、肾脏指数和血糖浓度均极显著降低,脾脏指数极显著提高,其中空腹血糖(FBG)比对照模型组小鼠下降20.38%,餐后血糖(PBG)下降39.07%;饲喂添加5%脱脂预蛹粉饲料的糖尿病模型小鼠,其控制血糖效果明显低于预蛹粉添加组。试验组糖尿病模型小鼠饲喂添加1%、5%和10%预蛹粉的饲料后的糖化血红蛋白(HbA1 c)均极显著低于对照模型组小鼠,分别降低了31.39%、45.89%和54.42%;5%和10%预蛹粉添加组模型小鼠的血清C肽极显著高于对照模型组小鼠,分别增加了18.97%和29.31%。试验结果显示,家蚕预蛹粉能有效控制糖尿病模型小鼠的血糖水平,并改善小鼠的基本生理状况和脏器指数,但总体效果略低于拜糖平添加组;脱脂后的家蚕预蛹粉的降血糖效果显著降低,提示其降血糖活性分子可能存在于脂溶性物质中。     

犬甲状腺机能减退并发糖尿病的中西医结合诊疗

犬甲状腺机能减退是由于甲状腺功能异常而引起甲状腺激素分泌不足或合成减少导致犬的内分泌紊乱的一类综合性疾病。长期的甲状腺激素分泌不足,可能继发糖尿病的发生。通过对1例患犬临床症状表现为全身被毛稀疏,多饮多尿多食,双眼白内障等,结合实验室检查(血常规、生化、甲状腺功能检查),总甲状腺(T4)<6.5,参考范围15 nmol/L^50nmol/L,血糖(GLU)20.7 mmol/L,参考范围3.9 mmol/L^8.0 mmol/L,确诊为甲状腺机能减退并发糖尿病。经补充左甲状腺素片治疗甲状腺机能减退,同时用胰岛素控制血糖,再结合中药和针灸辅助治疗病情得到缓解,为临床诊疗该类病提供了参考。     

Apoptosis and its modulation in type Ⅰ diabetes mellitus

Apoptosis, also known as programmed cell death, is a normal process contributing to tissue tumor during development and in the adult.During development apoptosis is involved in tissue homeostasis and eliminating nonfunctional, superfluous or harmful cells. It is an active process controlled by some gene and factors such as caspases, bcl-2, Fas/FasL and NO. Type 1 diabetes mellitus is regarded as a chronic autoimmune disease resulting from progressive destruction of insulin-producing β-cells in the pancreas. The relationship between apoptosis with its modulation and type 1 diabetes mellitus was reviwed.